Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-09

Clinical Trial Update: A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 clinical trial studying Evacetrapib in participants with severe renal impairment and in healthy participants; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evacetrapib

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cardiovascular Disease | Phase 1 | Status: COMPLETED | Results posted: 2018-10-09